Apple is increasingly focusing on building its own devices and expanding its ecosystem by taking steps towards a more native experience for users and relying less on third-party accessories. While the Cupertino-based tech giant's HomePod and AppleTV have left quite the mark in the smart home category, it generally relies more on outsourcing cameras and other hardware for smart homes. Now, a new report suggests that the company intends to create a fully integrated experience by developing its own smart home accessories. Gurman hints about Apple working on making smart home products like security cameras for a more integrated experience […]
We’re continuing our Best of Black Friday posts today with a look at the best current deals on power stations and their respective bundle options. Folks across the country and beyond have been steadily investing more and more in the industry for a vari...
Blizzard has announced that two decades after its release, World of Warcraft is finally going to let players build a home and live in it. The feature has long been requested by WoW players and now it’s finally coming in the game’s next expansion.Read m...
Guild Wars 2: Janthir Wilds will receive the Godspawn update, adding a new 50-player boss battle, a new 10-player raid, and a legendary spear. Guild Wars 2: Janthir Wilds is getting the first major update "Godspawn" on November 19th, expanding the story with new story chapters The MMORPG Guild Wars 2 by ArenaNet is receiving its first major update for the Janthir Wilds expansion soon. It's the first of three major updates, and it'll land on November 19. The update will add new content to the game for the players. The Janthir Wilds expansion DLC was released in August this year, […]
In what substantially bolsters the veracity of the tagline that the GLP-1 anti-obesity drugs constitute one of the most compelling cases of thematic investing this decade, UBS is out today with a fresh investment note that illustrates the scale of this ongoing paradigm shift in how the healthcare industry deals with the persistent obesity pandemic. The GLP-1 hormone suppresses hunger and regulates the production of insulin and glucose. After a meal, this hormone raises the level of insulin, which decreases blood glucose levels, and reduces the rate at which the stomach empties its contents into the small intestine, creating a […]
With potentially $100 billion in annual sales by 2030 up for grabs, the competition in the GLP-1 weight loss drugs space is predictably heating up, with Eli Lilly and Company (LLY) going head-to-head with the European pharma giant Novo Nordisk (NVO). A new study has upended the perceived parity between these two pharma heavy-weights, however, with Eli Lilly and Company managing to score a direct hit against Novo Nordisk. JAMA Study: Use Of Eli Lilly And Company's GLP-1 Agonist Tirzepatide Was Associated With Significantly Greater Weight Loss Than Novo Nordisk's Semaglutide For the benefit of those who might not be […]
From offering a viable solution to the obesity pandemic and its comorbidities to reducing the demand for ResMed's continuous Positive Airway Pressure (PAP) therapy devices that are used to treat the symptoms of sleep apnea, it is hardly surprising that GLP-1 drugs currently constitute one of Wall Street's biggest thematic investment ideas for the ongoing decade. Even so, researchers continue to discover new use-cases for these miracle drugs, with the latest such discovery centering on alcohol addiction control. A Primer On GLP-1 Drugs The GLP-1 hormone suppresses hunger and regulates the production of insulin and glucose. After a meal, this […]
Wall Street is convinced that anti-obesity GLP-1 drugs constitute a thematic bull case, with Goldman Sachs recently pegging its estimate of annual global sales of these drugs at $130 billion by 2030. In fact, financial analysts have already begun to downgrade the long-term demand outlook for fast food giants such as McDonald's, based on assumptions that 7 percent of the total population in the US would be using GLP-1 drugs in the next 10 years, with the average caloric consumption of those users declining by around 20 percent. Yet, it is the exorbitant price tags of these drugs - at […]
Eli Lilly and Company (NYSE: LLY) is currently one of the two primary darlings of Wall Street when it comes to thematic investing around anti-obesity GLP-1 drugs, with Novo Nordisk constituting the other end of this emerging duopoly. Yet, it is the precise heft of these two pharma giants that continues to present emergent opportunities to their smaller counterparts, especially in obesity-related diseases such as the Metabolic dysfunction-Associated Steatohepatitis (MASH, previously known as Nonalcoholic Ateatohepatitis or NASH). For the benefit of those who might not be aware, MASH is a fatty liver disease that develops primarily due to metabolic disorders, including […]
Vampire Survivors draws tons of inspiration from Castlevania, so it is no surprise that the new Ode To Castlevania DLC is fantastic. I’m here to guide you through unlocking each Hero and evolving each weapon, because that’s how you’ll end up accessing ...
I started playing Overwatch in 2019. By the time I was pushing payloads and getting Play of the Game with a well-placed Tactical Visor, a lot of the old hero kits and team compositions that were infamous when the hero shooter launched in 2016 were more...
In what substantially bolsters the veracity of the tagline that the GLP-1 anti-obesity drugs constitute one of the most compelling cases of thematic investing this decade, UBS is out today with a fresh investment note that illustrates the scale of this ongoing paradigm shift in how the healthcare industry deals with the persistent obesity pandemic. The GLP-1 hormone suppresses hunger and regulates the production of insulin and glucose. After a meal, this hormone raises the level of insulin, which decreases blood glucose levels, and reduces the rate at which the stomach empties its contents into the small intestine, creating a […]
With potentially $100 billion in annual sales by 2030 up for grabs, the competition in the GLP-1 weight loss drugs space is predictably heating up, with Eli Lilly and Company (LLY) going head-to-head with the European pharma giant Novo Nordisk (NVO). A new study has upended the perceived parity between these two pharma heavy-weights, however, with Eli Lilly and Company managing to score a direct hit against Novo Nordisk. JAMA Study: Use Of Eli Lilly And Company's GLP-1 Agonist Tirzepatide Was Associated With Significantly Greater Weight Loss Than Novo Nordisk's Semaglutide For the benefit of those who might not be […]
From offering a viable solution to the obesity pandemic and its comorbidities to reducing the demand for ResMed's continuous Positive Airway Pressure (PAP) therapy devices that are used to treat the symptoms of sleep apnea, it is hardly surprising that GLP-1 drugs currently constitute one of Wall Street's biggest thematic investment ideas for the ongoing decade. Even so, researchers continue to discover new use-cases for these miracle drugs, with the latest such discovery centering on alcohol addiction control. A Primer On GLP-1 Drugs The GLP-1 hormone suppresses hunger and regulates the production of insulin and glucose. After a meal, this […]
Wall Street is convinced that anti-obesity GLP-1 drugs constitute a thematic bull case, with Goldman Sachs recently pegging its estimate of annual global sales of these drugs at $130 billion by 2030. In fact, financial analysts have already begun to downgrade the long-term demand outlook for fast food giants such as McDonald's, based on assumptions that 7 percent of the total population in the US would be using GLP-1 drugs in the next 10 years, with the average caloric consumption of those users declining by around 20 percent. Yet, it is the exorbitant price tags of these drugs - at […]
Eli Lilly and Company (NYSE: LLY) is currently one of the two primary darlings of Wall Street when it comes to thematic investing around anti-obesity GLP-1 drugs, with Novo Nordisk constituting the other end of this emerging duopoly. Yet, it is the precise heft of these two pharma giants that continues to present emergent opportunities to their smaller counterparts, especially in obesity-related diseases such as the Metabolic dysfunction-Associated Steatohepatitis (MASH, previously known as Nonalcoholic Ateatohepatitis or NASH). For the benefit of those who might not be aware, MASH is a fatty liver disease that develops primarily due to metabolic disorders, including […]